Can Apple's Slim iPhone And Cheaper Macs Reverse The 2025 Stock Slump?
On Monday, Bank of America Securities analyst Wamsi Mohan reaffirmed a Buy rating on Apple, maintaining a price forecast of $235.
As Apple prepares to release its fiscal third-quarter earnings on July 31, investor sentiment, as noted by Mohan, remains somewhat subdued.Key concerns include escalating tariff-related costs, scrutiny from the Department of Justice regarding Google's traffic acquisition cost (TAC) payments, ongoing headwinds for the App Store, and the perceived slow pace of Apple's advancements in artificial intelligence.
Nevertheless, the impending earnings call is expected to shift focus towards gross margin trends and the projected recovery trajectory fueled by forthcoming product launches.
For fiscal third-quarter 2025, Mohan projects revenue of $90.2 billion and earnings per share (EPS) of $1.45, figures that slightly surpass consensus Street estimates of $89.3 billion and $1.43, respectively.
The analyst anticipates a gross margin of approximately 46.1%, aligning with Apple's guidance midpoint, despite the absorption of an estimated $900 million in tariff-related costs.
Looking ahead to the fourth quarter, projections indicate revenue of $99.5 billion and EPS of $1.66, largely in line with Street expectations.
While gross margin is projected to dip to 45% due to an additional $1 billion in tariff impact, Mohan views this quarter as a trough, with margins expected to improve heading into fiscal 2026.
Mohan noted that a key driver of this expected rebound is the highly anticipated 'slim' iPhone, potentially branded as the iPhone 'Air,' which Apple is likely to launch in fall 2025.
The analyst said that this model, expected to replace last year's Plus version, will reportedly have a 6.6-inch display, measure just 6mm thick, and carry a price tag $100 higher than the Plus.
He noted that the shift in product mix toward higher average selling prices (ASP) is anticipated to drive gross margin expansion and boost replacement rates. Mohan modeled stronger iPhone sales in the September and December quarters on the back of this launch.
On the Mac front, Apple is expected to benefit from the March launch of the new MacBook Air featuring the M4 chip, which provides improved performance at a reduced entry price of $999, or $100 lower than its predecessor, the analyst noted.
He said this is expected to drive better-than-seasonal Mac revenue in the June and December quarters. Similarly, Mohan said the iPad segment could receive a boost from the expected fall launch of iPad Pro models equipped with the M5 chip. The analyst anticipates revenue growth in iPads driven by higher ASPs and product upgrades.
Apple's Services segment continues to show steady growth, Mohan noted. For the third quarter, he expects Services revenue of $27.1 billion, up 2% quarter-over-quarter and 12% year-over-year.
Substantial year-over-year gains are projected across the App Store (+12%), Licensing (+18%), Subscriptions (+9%), and Apple Pay (+18%), as per the analyst.
For the fourth quarter, Services are projected to rise another 3% sequentially to $28 billion, again marking a 12% annual increase, with Licensing and Apple Pay both expected to grow over 20% year-over-year, Mohan noted.
Mohan slightly raised estimates for the full fiscal year 2025. Revenue is now forecast at $409 billion (up from $408 billion), and EPS at $7.15 (up from $7.13). The price forecast remains $235, based on a 29x multiple of fiscal 2026 estimated EPS of $8.20.
While Apple faces near-term margin pressure and regulatory noise, Mohan noted upside potential in new product cycles, improving Services momentum, and ASP-driven gross margin recovery, positioning the stock for renewed strength in the back half of the year.
AAPL Price Action: Apple stock is trading higher by 0.10% to $214.06 at last check on Monday.
Image via Shutterstock
Latest Ratings for AAPL
Date
Firm
Action
From
To
Mar 2022
Barclays
Maintains
Equal-Weight
Feb 2022
Tigress Financial
Maintains
Strong Buy
Jan 2022
Credit Suisse
Maintains
Neutral
View More Analyst Ratings for AAPL
View the Latest Analyst Ratings
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Can Apple's Slim iPhone And Cheaper Macs Reverse The 2025 Stock Slump? originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever
Key Points Johnson & Johnson has a historically high yield, and it is a Dividend King. Medtronic is two years shy of Dividend King status and has a historically high yield. Merck's dividend has grown steadily, though not annually, for decades. 10 stocks we like better than Johnson & Johnson › Healthcare stocks aren't exactly known for offering large yields, with the average healthcare stock at just 1.8% or so. You can do better than that and get reliable dividend stocks while you are at it. All you need to do is buy Johnson & Johnson (NYSE: JNJ), Medtronic (NYSE: MDT), and Merck (NYSE: MRK), and then hold them forever. Here's what you need to know. 1. Johnson & Johnson is a Dividend King When it comes to reliable dividend stocks, the highest honor that is bestowed on a company is the rank of Dividend King. A company has to increase its dividend annually for five decades to earn that title. Johnson & Johnson's dividend streak is up to 63 years, which is the longest streak of any healthcare company. The dividend yield is an attractive 3.1%. That yield is not only well above the healthcare average, it's also toward the high end of Johnson & Johnson's historical yield range. Historically speaking, the stock looks like it is on sale despite what is a very impressive and well-run business. The company is an industry-leading pharmaceutical and medical device maker. That said, there's a bit of uncertainty here today. Johnson & Johnson is facing a fairly large class action lawsuit around talcum powder it sold. It will likely survive through this, but the overhang of the suit could be a drag for a while. If that doesn't bother you, though, jump in. One thousand dollars will get you around five shares of Johnson & Johnson stock. 2. Medtronic is two years shy of being a Dividend King Medtronic has increased its dividend annually for 48 consecutive years. That's not as good as the streak Johnson & Johnson has built, but it is still pretty darn impressive. Medtronic is focused exclusively on medical devices, and it has a dividend yield of roughly 3.1% today. Like Johnson & Johnson, Medtronic is one of the largest players in the sectors it serves. Medtronic's dividend yield also happens to be historically high right now. Unlike with Johnson & Johnson, however, the problems here don't involve a large class action lawsuit. Medtronic's growth has slowed down, thanks at least in part to a period in which few new products were being introduced. Management is working to fix the issue. For starters, new products are again starting to come to market (innovation is lumpy, so this isn't shocking). The company is also attempting to refocus around its most desirable businesses. The end result is likely to be a more profitable and faster-growing company. But for now, Wall Street remains in a "show me" mood, which is an opportunity for buy-and-hold dividend investors to jump aboard an industry-leading medical device maker while it has a historically attractive dividend yield. A $1K investment will net you roughly 10 shares of Medtronic. 3. Merck's dividend record is good, but not kingly Merck is one of the largest pharmaceutical companies on the planet. As noted, innovation is lumpy, and that's particularly true when it comes to drugs. Add in the fact that drug patents only allow exclusivity for so long, and there's always a cliff somewhere down the line for drugmakers with blockbuster products. This is the nature of Merck's business, and there's nothing that can be done about it. Sometimes it just takes a little bit longer than hoped to find a new drug to replace the ones that are losing patent protections. What's actually impressive is that, despite the ups and downs, Merck has managed to keep its dividend growing over time. That hasn't happened every single year -- there have been some lengthy periods when the dividend was static. But generally higher over time is still quite attractive when you add it to a historically high 3.9% or so dividend yield. There's no telling when Merck will find its next blockbuster. It may develop it in-house, or it might buy a company to acquire an attractive drug. But history suggests that buying and holding this giant drugmaker has been a win for dividend lovers with a holding period of "forever." Investing $1,000 here will allow you to buy about 11 shares of Merck. What are you really buying? Johnson & Johnson, Medtronic, and Merck are all high-yield healthcare stocks with strong dividend records. But that's not really all you're buying here. The truth is, healthcare is a very complex sector, and these three industry giants are standout businesses. You may not be expert enough in healthcare to keep up with the innovation in the industry, but these three companies are experts. In other words, you're getting well-run businesses that are doing the heavy lifting in the healthcare sector so you don't have to be an expert. Along with that, you're getting attractive dividend yields backed by solid dividend histories. Should you buy stock in Johnson & Johnson right now? Before you buy stock in Johnson & Johnson, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Merck. The Motley Fool recommends Johnson & Johnson and Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever was originally published by The Motley Fool
Yahoo
8 minutes ago
- Yahoo
Ray Dalio Says 15% In Bitcoin Or Gold May Be Essential As Fiat Currencies Face Devaluation Risks
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Billionaire investor Ray Dalio advised a 15% portfolio allocation to Bitcoin (CRYPTO: BTC) or gold, citing mounting U.S. debt concerns and potential currency devaluation risks. What Happened: The Bridgewater Associates founder warned of a 'classic devaluation' scenario similar to the 1970s or 1930s in an appearance on the Master Investor Podcast, where fiat currencies could decline together against hard assets. 'If you were neutral on everything and optimizing your portfolio for the best return-to-risk ratio, you would have about 15% of your money in gold or Bitcoin,' Dalio stated. Don't Miss: 7,000+ investors have joined Timeplast's mission to eliminate microplastics— This AI-Powered Trading Platform Has 5,000+ Users, 27 Pending Patents, and a $43.97M Valuation — You Can Become an Investor for Just $500.25 Dalio expressed a strong preference for gold over Bitcoin, previously describing the precious metal as the 'purest play' for a store of value. Gold currently ranks as the second-largest reserve currency globally after the U.S. dollar, he noted. The billionaire holds both assets but maintains significantly larger gold positions than Bitcoin allocations. Why It Matters: The veteran investor highlighted critical fiscal challenges facing the United States. Federal government debt stands at 125% of GDP, with the fiscal deficit reaching 7% of GDP—the highest among industrialized nations. Dalio proposed a '3% solution' requiring immediate action to reduce the deficit from 7.5% to 3% of GDP through combined tax increases and spending cuts. While acknowledging Bitcoin's perceived value as alternative money with limited supply and global transaction benefits, Dalio questioned its effectiveness as a reserve Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Image via Shutterstock This article Ray Dalio Says 15% In Bitcoin Or Gold May Be Essential As Fiat Currencies Face Devaluation Risks originally appeared on
Yahoo
8 minutes ago
- Yahoo
UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover?
Key Points It isn't typical for UnitedHealth stock to finish a year lower than it started, let alone be down more than 40% as it is right now. Rising costs and uncertainty around healthcare reform are just a couple of the issues plaguing the stock. It's trading around multiyear lows, however, and is arguably a cheap buy. 10 stocks we like better than UnitedHealth Group › For years UnitedHealth Group (NYSE: UNH) has normally been a reliable dividend stock. But an abysmal start to 2025 has wiped out many of the gains that investors have achieved in recent years, with its five-year return now in negative territory. Year to date, the stock has fallen by nearly 45%, which is by no means normal for the healthcare stock. In fact, this is the worst it has performed since the Great Recession, when it tumbled by more than 54% in 2008. The big questions many investors are likely asking today are: Can it recover? Or is there more of a downfall to come for this once seemingly unstoppable stock? Big declines aren't the norm for UnitedHealth The past few years haven't been all that great for UnitedHealth, but by and large, this has been a fairly strong stock to own. It has typically outperformed the market. And outside of 2024 -- when it was down 4% -- the last time it finished a year in the red was (as noted) back in 2008, when the U.S. economy was in the midst of the Great Recession and the stock lost more than half of its value. Not only has UnitedHealth normally been a safe stock, it's also been a tremendous growth stock. Consider that if you invested $10,000 into its shares at the end of 2003, then 20 years later your investment would have been worth $181,000. But if you hung on until now, that investment would have fallen to a value of $101,000. While that's still a good return, it spotlights just how significant the decline has been this year, for a stock that's typically known for being a solid long-term investment. Still, the past doesn't predict the future. Why the company might face a tough road ahead The problem with UnitedHealth right now is that it's facing many challenges. Medical costs are up, and there's a lot of uncertainty in healthcare as the federal government looks to cut costs. Meanwhile, the Department of Justice is reportedly looking into UnitedHealth's billing practices. The danger is that the company may face financial repercussions and other headwinds, such as having to change its practices -- or at the very least, incurring higher-than-typical costs due to greater utilization rates. The latter, however, may be a shorter-term trend. Either way, this is a business known for consistently growing its operations, and that may not be a sure thing anymore. While UnitedHealth generated a healthy profit of more than $14.4 billion on revenue of $400.3 billion in 2024, investor concerns about long-term growth appear to be weighing on the stock. In May, the company suspended its outlook for the year; it also announced a change in CEO, with Andrew Witty stepping down for personal reasons and former CEO Stephen Hemsley taking over. Should you buy UnitedHealth stock today? While UnitedHealth stock has done well in previous years, that doesn't mean that it's a surefire bet to rebound soon. The good news is that it still has solid fundamentals. Since it's a key health insurer in the U.S., I'd be hesitant to count it out in the long run. There's some near-term risk and even some long-term uncertainty about how all the changes in the healthcare industry might pan out. But the stock is trading at levels it hasn't been at since 2020, and its valuation is just 12 times its trailing earnings. I think that gives it a good enough margin of safety at its current price, and that buying it today might prove to be a solid move. As long as you're willing to be patient, this can be a good stock to buy and hold. Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
